Nefilin (Tamsulosin Hydrochloride, Solifenacin Succinate)

Tamsulosin Hydrochloride and Solifenacin Succinate, the active ingredients in Nefilin, are an Alpha‑1 blocker and an Antimuscarinic presented as an oral tablet for oral use. The combination is indicated for men with benign prostatic hyperplasia and for patients experiencing overactive bladder symptoms such as urgency and frequency.

GNH USA supplies Nefilin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nefilin acts on the lower urinary tract to relieve obstruction and overactivity. - Benign prostatic hyperplasia (BPH): improves urinary flow and reduces bladder outlet obstruction. - Urinary retention associated with BPH: facilitates bladder emptying and decreases residual volume. - Overactive bladder: lessens urgency episodes and urinary frequency. - Urinary urgency: reduces sudden strong urges to void. - Urinary frequency: decreases the number of daily voids.

The following adverse reactions have been reported with the combination of tamsulosin and solifenacin.

Common Side Effects: - Dizziness: mild to moderate light‑headedness, especially after standing. - Dry mouth: reduced salivation leading to throat discomfort. - Constipation: slowed gastrointestinal transit. - Headache: transient cranial pain. - Blurred vision: temporary visual disturbances. - Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure, potentially causing fainting. - Priapism: prolonged, painful erection requiring urgent care. - Acute urinary retention: sudden inability to void. - Angle‑closure glaucoma: rapid increase in intra‑ocular pressure. - Allergic reactions: rash, swelling, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm.

Before initiating therapy, consider the following safety measures. - Blood pressure monitoring: assess for hypotension, especially after the first dose. - Urinary assessment: evaluate for existing retention or severe obstruction. - Hepatic and renal function: adjust use if impairment is present. - Concomitant medications: review for other alpha‑blockers or antimuscarinics. - Narrow‑angle glaucoma: avoid in patients with this condition. - Store at ambient temperature: keep in the original container, protect from moisture.

Potential drug‑drug interactions should be evaluated prior to prescribing.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase tamsulosin levels. - Other alpha‑blockers (e.g., prazosin): risk of additive hypotension. - Potent antimuscarinics (e.g., oxybutynin): may exacerbate urinary retention.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin): may reduce tamsulosin efficacy. - Diuretics: monitor electrolytes and blood pressure. - Antihistamines: may increase anticholinergic burden. - Antidepressants with anticholinergic properties: watch for additive dry‑mouth and constipation.